Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

Howard S. Hochster, Michael D. Green*, Ronald H. Blum, James C. Wernz, James L. Speyer, Franco M. Muggia

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.

Original languageEnglish
Pages (from-to)275-278
Number of pages4
JournalInvestigational New Drugs
Issue number3
StatePublished - Sep 1986
Externally publishedYes


  • 4-demethoxydaunorubicin
  • idarubicin
  • non-small cell lung cancer
  • oral cytotoxic
  • phase II clinical trial


Dive into the research topics of 'Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial'. Together they form a unique fingerprint.

Cite this